866-997-4948(US-Canada Toll Free)

Published on : May 12, 2016

The global market for the treatment of dementia syndrome and movement disorders has been reporting a significant rise at a significant pace. The increasing base of the geriatric population across the world is fueling the demand for the treatment of dementia syndrome and movement disorders extensively. However, strict policies and norms pertaining to the treatment of dementia syndrome and other movement disorders, together with a prolonged period for approval of drugs needed in these treatments, are expected to limit the growth of this market in the coming years.

North America Market for Treatment of Dementia Syndrome and Movement Disorders to Reach US$9 bn by 2020
North America has acquired the leading position in the global market for the treatment of dementia syndrome and movement disorders. The rising incidence of neurodegenerative disorders has driven this market substantially in North America since the last few years. In addition to this, the increasing awareness pertaining to dementia syndrome and other movement disorders is expected to propel this regional market to around US$9 bn by 2020.

Europe has occupied the second position in the global market for the treatment of dementia syndrome and movement disorders. The rising prevalence of mental disorders in Europe is the key driving force behind the growth of this regional market. Along with this, the increasing number of awareness programs intended to curb dementia syndrome and other movement disorders are projected to boost this regional market considerably in the coming years.

Asia Pacific to Report Highest Growth over Next Few Years
Asia Pacific is anticipated to report the highest growth in the global market for the treatment of dementia syndrome and movement disorders over the next few years. The huge base of geriatric population and the increasing penetration of health insurance in Asia Pacific is likely to fuel the demand for the treatment of these diseases in this region over the coming years.

AstraZeneca GmbH, Bristol-Myers Squibb Co., Valeant Pharmaceuticals, Sanofi, Baxter, Roche, Pfizer Inc., Abbott Laboratories Inc., Novartis AG, and Merck & Co. Inc. are some of the key participants in the worldwide market for the treatment of dementia syndrome and movement disorders.